Patents Examined by Joseph R. Kosack
  • Patent number: 10925968
    Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: February 23, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, Heehyoung Lee, Tong Zhu, Henry Hongjun Ji
  • Patent number: 10927128
    Abstract: The present invention relates to compounds having pharmacological activity towards the sigma (?) receptor, and more particularly to oxadiazaspiro compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular against drug abuse and addiction.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: February 23, 2021
    Inventors: Marina Virgili-Bernado, Carmen Almansa-Rosales, Carlos Alegret-Molina
  • Patent number: 10919855
    Abstract: An alternative and improved process for the preparation of Apremilast (Formula I) and Apremilast form B or a pharmaceutically acceptable salt thereof is provided. The novel process includes hydrogenation in acetone, Cyclization and acetylation followed by condensation in methyl isobutyl ketone (MIBK) and acetic acid mixture in specific volume ratios.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 16, 2021
    Inventors: Dhananjay G. Sathe, Arijit Das, Bhavesh B. Patel, Dipak Subhash Patil, Ashok Govind Matale, Eknath Kamalakar Kshirsagar
  • Patent number: 10919868
    Abstract: Provided are benzotriazole derivative compounds of the general formula that are novel compounds capable of strongly absorbing light in the ultraviolet range, particularly 300-330 nm, while strongly absorbing light in the visible light short-wavelength range up to around 450 nm and being used suitably as a light absorber having high light fastness with a light-blocking function over an extended period of time. Preferably, R1 is a hydrogen atom or alkyl group, R2 is a C1-8 alkyl group, R3 is a hydrogen atom, alkyl group, acryloyloxyalkyl group, or methacryloyloxyalkyl group.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: February 16, 2021
    Inventors: Tomoyuki Ishitani, Toshiyuki Uesaka, Takuya Iwamoto
  • Patent number: 10913740
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: February 9, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E. L. Brandt, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • Patent number: 10907046
    Abstract: Provided herein are compounds that are able to bind metal ions (e.g., free metal ions or metal ions bound to low affinity ligands) in a sample or subject. Also provided herein are methods of using the compounds for chelating metal ions and for the treatment of diseases associated with abnormal levels of metal ions. Methods of preparing the compounds and pharmaceutical compositions are also provided.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: February 2, 2021
    Assignees: The General Hospital Corporation, Northeastern University
    Inventors: Hak Soo Choi, Jonghan Kim, Georges El Fakhri
  • Patent number: 10906881
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: February 2, 2021
    Assignee: CORTEXYME, INC.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey C. Lynch, Craig Coburn, Joseph Vacca
  • Patent number: 10905668
    Abstract: The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them: wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 2, 2021
    Assignee: BIOGEM S.C. A R.L.
    Inventors: Claudio Pisano, Sabrina Dallavalle, Raffaella Cincinelli, Lucio Merlini
  • Patent number: 10907047
    Abstract: The present application relates to novel whitening agents for cellulosic substrates. The whitening agents are comprised of at least two constituents: at least one chromophore constituent and at least one polymeric constituent. Suitable chromophore components generally fluoresce blue, red, violet, or purple color when exposed to light, or they may absorb light to reflect these same shades. The whitening agents are further characterized by the polymeric component comprising at least two repeating glycerol units. This disclosure also relates to laundry care compositions including but not limited to liquid and/or powder laundry detergent formulations and rinse added fabric softening (RAFS) compositions that comprise such whitening agents.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: February 2, 2021
    Assignee: Milliken & Company
    Inventors: Eduardo Torres, Gregory Scot Miracle
  • Patent number: 10894247
    Abstract: A fluidized-bed catalyst suitable for the production of halogenated aromatic nitriles includes an active component and a support. The active component is a complex having the following composition expressed in atomic ratio: VPaCrbAcMdOx, wherein A represents at least one metal selected from the group consisting of alkali metals and alkaline earth metals; M represents at least one element selected from the group consisting of Ti, Zr, Hf, La, Ce, Nb, Mo, W, Co, Zn, Fe, Ni, B, Sb, Bi, As, Ga, Ge, Sn, and In; in the XRD spectrum of the catalyst, diffraction peaks are present at 2?=27.8±0.5° and 2?=13.8±0.5°, and the ratio of the height (I1) of the diffraction peak at 2?=27.8±0.5° to the height (I2) of the diffraction peak at 2?=13.8±0.5° is 3.5-6, i.e. I1:I2=3.5-6.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: January 19, 2021
    Inventors: Weimin Yang, Longqin Gu, Wei Zeng, Liang Chen, Junfeng Xu
  • Patent number: 10894776
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: January 19, 2021
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler, Kumaraswamy Emayan, Jingyuan Ma
  • Patent number: 10889580
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating non-alcoholic steatohepatitis are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: January 12, 2021
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Patent number: 10889554
    Abstract: The present application is directed to excimer forming compounds of Formula I: W—V—[Y]n wherein W is an excimer forming fluorophore, V is a linker moiety, Y is a metal ion coordinating moiety and n is 1, 2 or 3. In particular, the application is directed to excimer forming compounds for the detection of proximally phosphorylated sites including those found on polypeptides, proteins, pyrophosphate and RNA, for example in aqueous solution, polyacrylamide gels blotting membranes, solid-support assays and in cell culture samples.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 12, 2021
    Assignee: The Governing Council of the University of Toronto
    Inventors: Patrick Thomas Gunning, Dziyana Kraskouskaya
  • Patent number: 10882870
    Abstract: The present invention relates to a crystalline metal organic framework which comprises repeating units of formula (RR)-(IA) or (SS)-(IA) or (RS)-(IA) or (SR)-(IA); or alternatively of formula (RR)-(IB) or (SS)-(IB) or (RS)-(IB) or (SR)-(IB) and a composition containing it. It also relates to processes for their preparation and their uses as a separation agent and as a catalyst.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: January 5, 2021
    Inventors: Mᵃ de las Nieves Corella Ochoa, Vanesa Lillo García, Jose Ramón Galán Mascaros
  • Patent number: 10886479
    Abstract: The present invention provides a photoelectric conversion element exhibiting excellent responsiveness, and excellent photoelectric conversion efficiency in a case where the photoelectric conversion film is a thin film, an optical sensor, an imaging element which include the photoelectric conversion element, and a compound. The photoelectric conversion element of the present invention includes a conductive film, a photoelectric conversion film, and a transparent conductive film, in this order, in which the photoelectric conversion film contains a compound represented by Formula (1) and having a structure represented by Formula (2).
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: January 5, 2021
    Assignee: FUJIFILM Corporation
    Inventors: Tomoaki Yoshioka, Kimiatsu Nomura, Eiji Fukuzaki
  • Patent number: 10875865
    Abstract: Disclosed are a class of URAT1 inhibitor compounds and the use of such compounds. These compounds are compounds represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on hURAT1-transported uric acid in HEK293 transfected cells, and show that such compounds have a good potential for application in the treatment of hyperuricemia or gout.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: December 29, 2020
    Inventors: Dongfang Shi, Changjin Fu, Xi Cheng, Jianghua Zhu, Jie Gu
  • Patent number: 10865336
    Abstract: A polymer consisting of small functional molecules can be integrated into solar thermal fuels in the solid-state for solar energy harvesting and storage. In certain embodiments, a solar energy storage device can include one or more layers of photoswitchable moieties associated with a polymer. Such solar thermal fuel polymers can be used to enable deposition from low concentration solutions, resulting in uniform and large-area thin-films. This approach enables conformal deposition on a variety of conducting substrates that can be either flat or structured and control over film growth via electrodeposition conditions and results in highly uniform and large-area thin films.
    Type: Grant
    Filed: December 11, 2016
    Date of Patent: December 15, 2020
    Inventors: Jeffrey C. Grossman, David Zhitomirsky
  • Patent number: 10857170
    Abstract: A SIRT6 activating molecule as shown in Tables 1-3 or a compound according to a pharmacophore as described herein.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: December 8, 2020
    Assignee: SirTLab Corporation
    Inventors: Haim Yosef Cohen, Yariv Kanfi
  • Patent number: 10858315
    Abstract: Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ellman-chiral auxiliaries and the recrystallization and separation of optical isomers. According to the above method, high-purity N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide with excellent quality can be produced at room temperature by improving cryogenic process conditions necessary for realizing high optical purity, and thus the trimming due to the process failure rate can be remarkably reduced.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: December 8, 2020
    Inventors: Byoung Young Woo, Ki-Wha Lee, Jihae Lee, Chang Soon Choi, Miyoung Park, Young-Ho Park, Sarva Jayaprakash, Sridhar Regati, Mamidi Srinivas, Krushnakant Patel, M. Ramamohan
  • Patent number: 10858306
    Abstract: The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: December 8, 2020
    Inventors: François Guerard, Jean-François Gestin, Martin W. Brechbiel, Yong-Sok Lee